MeiraGTx’s Parkinson’s gene therapy shows promise in Phase I/II study
The AAV-GAD bridging study met the primary endpoint of safety and tolerability, and showed early promise in Parkinson’s patients.
Healthcare
Charting the road to operational success in clinical trials
Terumo and Charles River demonstrate effectiveness of CGT manufacturing device
Advancing quality control measures vital for cell and gene therapy development
NHS investment critical to drive cell and gene therapy research
Gene therapy for rare neuropathy displays potential in NIH trial
Increased global deaths from fungal disease highlight disease management obstacles
Covid-19 pandemic accelerated digital transformation progress
